Search

Author/Creator Chi, Kim N

1. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Issue 5 (May 2019)

Authors:
Fizazi, Karim; Tran, NamPhuong; Fein, Luis; Matsubara, Nobuaki; Rodriguez-Antolin, Alfredo; Alekseev, Boris Y; Özgüroğlu, Mustafa; Ye, Dingwei; Feyerabend, Susan; Protheroe, Andrew; Sulur, Giri; Luna, Yesenia; Li, Susan; Mundle, Suneel; Chi, Kim N
Journal:
Lancet oncology
Issue:
Volume 20:Issue 5(2019)
Page Start:
686
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Apalutamide for metastatic, castration‐sensitive prostate cancer in the Japanese population: A subgroup analysis of the randomized, double‐blind, placebo‐controlled phase 3 TITAN study. (8th December 2020)

Authors:
Uemura, Hirotsugu; Arai, Gaku; Uemura, Hiroji; Suzuki, Hiroyoshi; Iijima, Kazuyoshi; Nishimura, Kazuo; Fujii, Koji; Hatayama, Tomoyoshi; Aoyama, Junya; Deprince, Kris; Lopez‐Gitlitz, Angela; McCarthy, Sharon; Larsen, Julie S; Li, Jinhui; Chi, Kim N
Journal:
International journal of urology
Issue:
Volume 28:Number 3(2021)
Page Start:
280
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Biallelic tumour suppressor loss and DNA repair defects in de novo small‐cell prostate carcinoma. Issue 2 (28th August 2018)

Authors:
Chedgy, Edmund CP; Vandekerkhove, Gillian; Herberts, Cameron; Annala, Matti; Donoghue, Adam J; Sigouros, Michael; Ritch, Elie; Struss, Werner; Konomura, Saki; Liew, Janet; Parimi, Sunil; Vergidis, Joanna; Hurtado‐Coll, Antonio; Sboner, Andrea; Fazli, Ladan; Beltran, Himisha; Chi, Kim N; Wyatt, Al...
Journal:
Journal of pathology
Issue:
Volume 246:Issue 2(2018)
Page Start:
244
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Comparative Survival of Asian and White Metastatic Castration-Resistant Prostate Cancer Men Treated With Docetaxel. Issue 2 (29th January 2020)

Authors:
Halabi, Susan; Dutta, Sandipan; Tangen, Catherine M; Rosenthal, Mark; Petrylak, Daniel P; Thompson, Ian M; Chi, Kim N; De Bono, Johann S; Araujo, John C; Logothetis, Christopher; Eisenberger, Mario A; Quinn, David I; Fizazi, Karim; Morris, Michael J; Higano, Celestia S; Tannock, Ian F; Small, Eri...
Journal:
JNCI cancer spectrum
Issue:
Volume 4:Issue 2(2020)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial. Issue 11 (November 2017)

Authors:
Beer, Tomasz M; Hotte, Sebastien J; Saad, Fred; Alekseev, Boris; Matveev, Vsevolod; Fléchon, Aude; Gravis, Gwenaelle; Joly, Florence; Chi, Kim N; Malik, Zafar; Blumenstein, Brent; Stewart, Patricia S; Jacobs, Cindy A; Fizazi, Karim
Journal:
Lancet oncology
Issue:
Volume 18:Issue 11(2017:Nov.)
Page Start:
1532
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trial. Issue 4 (April 2017)

Authors:
Chi, Kim N; Higano, Celestia S; Blumenstein, Brent; Ferrero, Jean-Marc; Reeves, James; Feyerabend, Susan; Gravis, Gwenaelle; Merseburger, Axel S; Stenzl, Arnulf; Bergman, Andries M; Mukherjee, Som D; Zalewski, Pawel; Saad, Fred; Jacobs, Cindy; Gleave, Martin; de Bono, Johann S
Journal:
Lancet oncology
Issue:
Volume 18:Issue 4(2017:Apr.)
Page Start:
473
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study. Issue 11 (November 2019)

Authors:
Agarwal, Neeraj; McQuarrie, Kelly; Bjartell, Anders; Chowdhury, Simon; Pereira de Santana Gomes, Andrea J; Chung, Byung Ha; Özgüroğlu, Mustafa; Juárez Soto, Álvaro; Merseburger, Axel S; Uemura, Hirotsugu; Ye, Dingwei; Given, Robert; Cella, David; Basch, Ethan; Miladinovic, Branko; Dearden, Lindsa...
Journal:
Lancet oncology
Issue:
Volume 20:Issue 11(2019)
Page Start:
1518
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial. Issue 10295 (10th July 2021)

Authors:
Sweeney, Christopher; Bracarda, Sergio; Sternberg, Cora N; Chi, Kim N; Olmos, David; Sandhu, Shahneen; Massard, Christophe; Matsubara, Nobuaki; Alekseev, Boris; Parnis, Francis; Atduev, Vagif; Buchschacher, Gary L; Gafanov, Rustem; Corrales, Luis; Borre, Michael; Stroyakovskiy, Daniil; Alves, Gus...
Journal:
Lancet
Issue:
Volume 398:Issue 10295(2021)
Page Start:
131
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗